Rituximab + Prednisone + Doxorubicine + Cyclophosphamide + Vincristine
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Untreated T-cell Angioimmunoblastic Lymphoma
Conditions
Untreated T-cell Angioimmunoblastic Lymphoma
Trial Timeline
Dec 1, 2005 → Nov 1, 2012
NCT ID
NCT00169156About Rituximab + Prednisone + Doxorubicine + Cyclophosphamide + Vincristine
Rituximab + Prednisone + Doxorubicine + Cyclophosphamide + Vincristine is a phase 2 stage product being developed by Roche for Untreated T-cell Angioimmunoblastic Lymphoma. The current trial status is completed. This product is registered under clinical trial identifier NCT00169156. Target conditions include Untreated T-cell Angioimmunoblastic Lymphoma.
What happened to similar drugs?
1 of 4 similar drugs in Untreated T-cell Angioimmunoblastic Lymphoma were approved
Approved (1) Terminated (1) Active (2)
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00169156 | Phase 2 | Completed |
Competing Products
15 competing products in Untreated T-cell Angioimmunoblastic Lymphoma